openPR Logo
Press release

Ulcerative Colitis Market: Quantifying Market Opportunities Through Market Sizing And Market Forecasting Estimated By Global Key Players Abbvie Inc., Celltrion Healthcare, Johnson And Johnson, F. Hoffmann-La Roche Ag, Warner Chilcott, Janssen Pharmaceutic

02-15-2019 08:22 AM CET | Health & Medicine

Press release from: Coherent Market Insights

Global Ulcerative Colitis Market

Global Ulcerative Colitis Market

Ulcerative colitis is the most common type of inflammatory bowel disease that affects the colon (lining of the large intestine) and rectum. The inflammation produces tiny sores called ulcers. These disease can affect people of any age, though prevalence is especially high among people under 30 years of age. The major symptoms of this disease are diarrhea, belly pain/cramps, bleeding from the rectum, also other indications are sudden and unexplained weight loss, loss of appetite, joint pain, eye disease, thickening of the intestinal wall, blood infection (sepsis), kidney stones and liver disease. The diagnosis of this disease can be carried out by physical examination using tests such as colonoscopy, endoscopy, biopsy, CT scan and blood test.

Get Exclusive Sample Report at: https://www.coherentmarketinsights.com/insight/request-sample/238

If ulcerative colitis persists for over 8 years or longer, it may lead to colon cancer. The people having mild symptoms of this disease can be cured by over the counter drugs such as Imodium therapy. However, transcription medicine such as steroid medicines and amino salicylates are widely used to treat the condition. In severe cases, the patient may need to undergo surgery to remove the colon, which also helps prevent colon cancer.

Global Key Players:

Some major companies playing leading role in ulcerative colitis market are
AbbVie Inc.
Hospira
Celltrion Healthcare
Johnson and Johnson
F. Hoffmann-La Roche AG
Warner Chilcott
Janssen Pharmaceuticals Inc.
Takeda Pharmaceuticals Company Ltd.

Ulcerative Colitis Market Taxonomy:

Global Market by Drug Type

Infliximab
Golimumab
Adalimumab
Vedolizumab
Mesalamine
Budesonide
Balsazide

Global Market by Dosage Form

Parenteral
Oral

Global Market by Geography

North America
Europe
APAC
Latin America
Middle East
Africa

Request For Customization @ https://www.coherentmarketinsights.com/insight/request-customization/238

High Prevalence In Developed Regions And Increasing Incidence Rate In Emerging Economies Will Play Major Role In Driving Growth Of The Ulcerative Colitis Market:

According to the study of CCFA, industrialized countries have highest incidence rate for ulcerative colitis. This disease is most prevalent in urban areas than in rural areas, also it can affect to any age group of people but most cases diagnosed are of the age in between 15 to 35. According the stats of World Gastroenterology Organization (WGO), there is rising incidence rate in emerging economies such as India. Due to changing diet and lifestyle pattern, the emerging economies will show high growth rate in incidence rate of ulcerative colitis in the near future.

According to data collected from various sources and compiled by Coherent Market Insights, Europe have the highest annual rate of incidence worldwide, followed by North America and the lowest in Asia and Middle East.

However, North America holds the largest share in the global ulcerative colitis market due to continuous improvements in drugs, increased uptake of medicines, awareness about treatment and increasing clinical research. APAC region will show high growth in ulcerative colitis market during forecast years (2017-2024), due to raising awareness about the treatment, changing lifestyle will cause to increase prevalence and incidence rate, entry of new drugs in the market also some companies losing their patent of ulcerative drugs in coming years, like Humira (adalimumab) lost its patent in 2016 and Remicade will lose its patent in 2018. Also, some drugs companies have launched their biosimilar drugs in ulcerative colitis industry. For example, in 2016, India-based Torrent Pharmaceuticals launched a biosimilar drug under the brand name Adfra to compete Humira. Humira is a trade name for adalimumab medication owned by AbbVie Inc.

Browse Research Report At: https://www.coherentmarketinsights.com/ongoing-insight/ulcerative-colitis-market-238

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Ulcerative Colitis Market: Quantifying Market Opportunities Through Market Sizing And Market Forecasting Estimated By Global Key Players Abbvie Inc., Celltrion Healthcare, Johnson And Johnson, F. Hoffmann-La Roche Ag, Warner Chilcott, Janssen Pharmaceutic here

News-ID: 1591057 • Views: 341

More Releases from Coherent Market Insights

The Emergence of COVID-19 to Augment the Growth of the Vaccine Adjuvant Market
According to the Centers for Disease Control and Prevention (CDC), adjuvant is an ingredient used in vaccines that helps create a stronger immune response in people receiving the vaccine. In other words, adjuvants help vaccines work better. Growth of the vaccine adjuvant market is mainly driven by the outbreak of COVID-19 (the global pandemic). The use of an adjuvant is of importance in a pandemic where there is significant demand
Cascades Inc. Launched Cascades Fluff and Tuff Toilet Papers and Paper Towels fo …
Growing demand for sanitation and hygiene products such as tissue products used in the food service and healthcare industry is fostering the growth of the tissue products market. Also, advancement in tissue manufacturing technology such as ADT, ATMOS, and NTT is again uplifting the growth of the market. For instance, in September 2017, Sofidel Group launched Papernet BioTech, a toilet paper with Biologic Active Tissue Paper technology. The non-pathogenic microorganisms
North America Is Projected To Hold a Dominant Position in the Global Peptide Syn …
The growing prevalence of infectious diseases is fostering the growth of the peptide synthesis market. For instance, according to an article published by the Centers for Disease Control and Prevention (CDC) in February 2020, reports that the number of visits with infectious and parasitic diseases to physician offices as the primary diagnosis was 15.5 million in 2016 in the U.S. Moreover, key players are adopting inorganic strategies such as collaborations
Bioivt Acquired Ascendance Biotechnology to Expand Its Presence in Organ-On-A-Ch …
Growing lung-based organ culture and increasing application in disease modeling, phenotypic screening, and patient stratification is expanding organ-on-a-chip market size. This device offers better clinical examinations compared to Petri dishes and animal testing, thus helping scientists and companies a better understanding regarding the functioning of internal organs such as lungs and brains. Moreover, increasing funding and initiatives by the government are again expected to foster the growth of the organ-on-a-chip

All 5 Releases


More Releases for Ulcerative

Ulcerative Colitis Market to Reach $4,785 Million by 2023
Advancements in ulcerative colitis treatment modalities has led to the emergence of biologics such as tumor necrosis factors (TNF) in developing drugs. This has led to the shift from traditional therapies towards engineered drugs that has also enhanced the efficacy rate of drugs. According to a new report published by Allied Market Research, titled, Ulcerative Colitis Market by Disease Type, Route of Administration, and Molecule Type: Global Opportunity Analysis and Industry
Drug for Ulcerative Colitis Market Insights, Forecast by 2025
This recently published report examines the global Drug for Ulcerative Colitis market for the projected period of 7-years, i.e. between 2018 and 2025. The report highlights the accomplishments and opportunities lies in the market throughout the forecasted period. The report offers the thorough information about the overview and the scope of the global Drug for Ulcerative Colitis market along with its drivers, restraints, and trends. It also classifies the market
Ulcerative Colitis Market 2022: Global Analysis By Trend & Key Players
Ulcerative Colitis Market Analysis, by Medication (5-Aminosalicylates, Steroids, Purine Analogs, Immunomodulators, and Biologics) by type (Ulcerative Proctitis, Proctosigmoiditis, Left-Sided Colitis, Pancolitis or Universal Colitis, and Fulminant Colitis), - Forecast to 2022 Market Synopsis of Global Ulcerative Colitis Market: Market Scenario: Ulcerative colitis is a type of inflammatory bowel disease (IBD) that affects the colon and rectum part of human body. Inflammation and ulcers are formed in the innermost lining of the colon and
Ulcerative Colitis Market and Forecast Analysis
Boston, MA ReportsWorldwide has announced the addition of a new report title Ulcerative Colitis Market and Forecast Analysis to its growing collection of premium market research reports. Ulcerative colitis is a chronic inflammatory bowel disease that is characterized by inappropriate diffuse inflammation of the rectal and colonic mucosa, which occurs in the innermost layer of the intestinal lining. Ulcerative colitis is a chronic, incurable disease with low mortality that is generally diagnosed
Ulcerative Colitis Market
Ulcerative colitis is the most common type of inflammatory bowel disease that affects the colon (lining of the large intestine) and rectum. The inflammation produces tiny sores called ulcers. These disease can affect people of any age, though prevalence is especially high among people under 30 years of age. The major symptoms of this disease are diarrhea, belly pain/cramps, bleeding from the rectum, also other indications are sudden and unexplained
Ulcerative Colitis Pipeline Analysis, 2016
Ulcerative colitis is an inflammatory condition of colon, in which ulcer is formed in the colon lining. In ulcerative colitis, inflamed colon develops small number of open lesion, that produce pus and mucous. The abnormal response of the immune system causes inflammation in the colon. The ulcerative colitis pipeline has more than 45 drugs. In pipeline analysis, drugs are analyzed based on route of administration and molecule type. The pipeline is